Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRSN Stock Forecast 2025-2026
$27.85
Current Price
$138.84M
Market Cap
Buy 0
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to MRSN Price Targets
+79.5%
To High Target of $50.00
+4.1%
To Median Target of $29.00
-2.2%
To Low Target of $27.25
MRSN Price Momentum
+1.5%
1 Week Change
+231.2%
1 Month Change
-56.0%
1 Year Change
-22.1%
Year-to-Date Change
-60.6%
From 52W High of $70.73
+434.5%
From 52W Low of $5.21
📊 TOP ANALYST CALLS
Did MRSN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mersana Therapeutics is one of their latest high-conviction picks.
Latest MRSN Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, MRSN has a neutral consensus with a median price target of $29.00 (ranging from $27.25 to $50.00). The overall analyst rating is N/A (N/A/10). Currently trading at $27.85, the median forecast implies a 4.1% upside. This outlook is supported by 0 Buy, 7 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRSN Analyst Ratings
0
Buy
7
Hold
0
Sell
MRSN Price Target Range
Low
$27.25
Average
$29.00
High
$50.00
Current: $27.85
Latest MRSN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRSN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | Guggenheim | Michael Schmitz | Neutral | Downgrade | $N/A |
| Nov 13, 2025 | BTIG | Justin Zelin | Neutral | Downgrade | $N/A |
| Nov 13, 2025 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $30.75 |
| Aug 14, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $36.00 |
| Aug 14, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $30.00 |
| May 16, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $5.00 |
| May 16, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $10.00 |
| Feb 6, 2025 | William Blair | Andy Hsieh | Outperform | Initiates | $N/A |
| Aug 27, 2024 | Citigroup | Ashiq Mubarack | Buy | Maintains | $5.00 |
| Aug 14, 2024 | Baird | Colleen Kusy | Neutral | Maintains | $3.00 |
| Mar 19, 2024 | JP Morgan | Brian Cheng | Neutral | Upgrade | $5.00 |
| Feb 29, 2024 | Truist Securities | Asthika Goonewardene | Buy | Upgrade | $9.00 |
| Feb 29, 2024 | Wedbush | David Nierengarten | Outperform | Upgrade | $7.00 |
| Feb 29, 2024 | Baird | Colleen Kusy | Neutral | Maintains | $5.00 |
| Feb 29, 2024 | Guggenheim | Michael Schmidt | Buy | Upgrade | $7.00 |
| Dec 4, 2023 | Citigroup | Ashiq Mubarack | Buy | Upgrade | $5.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2023 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Aug 8, 2023 | Credit Suisse | Outperform | Reiterates | $N/A | |
| Aug 7, 2023 | Needham | Buy | Reiterates | $N/A |
Mersana Therapeutics, Inc. (MRSN) Competitors
The following stocks are similar to Mersana Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mersana Therapeutics, Inc. (MRSN) Financial Data
Mersana Therapeutics, Inc. has a market capitalization of $138.84M with a P/E ratio of -2.0x. The company generates $33.18M in trailing twelve-month revenue with a -211.2% profit margin.
Revenue growth is -12.6% quarter-over-quarter, while maintaining an operating margin of -67.9% and return on equity of +727.6%.
Valuation Metrics
Market Cap
$138.84M
Enterprise Value
$83.22M
P/E Ratio
-2.0x
PEG Ratio
0.1x
Price/Sales
4.1x
Growth & Margins
Revenue Growth (YoY)
-12.6%
Gross Margin
N/A
Operating Margin
-67.9%
Net Margin
-211.2%
EPS Growth
-12.6%
Financial Health
Cash/Price Ratio
+40.5%
Current Ratio
1.4x
Debt/Equity
0.0x
ROE
+727.6%
ROA
-36.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mersana Therapeutics, Inc. (MRSN) Business Model
About Mersana Therapeutics, Inc.
What They Do
Develops innovative antibody-drug conjugates for cancer.
Business Model
Mersana Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on creating novel antibody-drug conjugates (ADCs) that target specific cancer cells. The company earns revenue through collaborations with major biopharmaceutical firms, funding for research and development, and potential future product sales from successful clinical trials.
Additional Information
Mersana's proprietary technology platforms, Dolasynthen and Immunosynthen, enhance the efficacy and safety of ADCs compared to earlier generations. The company's pipeline includes promising candidates like Emi-Le and XMT-2056, which are currently in Phase 1 trials, showcasing its commitment to addressing unmet needs in cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
102
CEO
Dr. Martin H. Huber M.D.
Country
United States
IPO Year
2017
Website
www.mersana.comMersana Therapeutics, Inc. (MRSN) Latest News & Analysis
Latest News
Quick Summary
Mersana Therapeutics (MRSN) reported a Q3 loss of $1.51 per share, worse than the expected loss of $1.44, but an improvement from a loss of $2.25 per share a year prior.
Why It Matters
Mersana Therapeutics' larger-than-expected quarterly loss may signal ongoing challenges, potentially affecting investor confidence and stock performance. However, lower losses year-over-year could indicate improvement.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of Mersana Therapeutics (MRSN) to Day One Biopharmaceuticals, offering $25 per share plus a non-tradable CVR for milestone payments.
Why It Matters
The investigation into Mersana Therapeutics' sale could signal potential legal issues or valuation concerns, impacting stock performance and investor sentiment regarding the deal.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Mersana Therapeutics shares surged after Day One Biopharmaceuticals announced an agreement to acquire the company for up to $285 million.
Why It Matters
Mersana Therapeutics' share price surge indicates strong market confidence following the acquisition deal, potentially signaling future growth and increased value for investors.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Mersana Therapeutics will hold a conference call on November 13, 2025, regarding its acquisition by Day One Biopharmaceuticals, featuring key executives and analysts.
Why It Matters
The acquisition of Mersana Therapeutics by Day One Biopharmaceuticals signals potential growth opportunities, market consolidation, and impacts on stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
An agreement with Day One Biopharmaceuticals includes $25 per share upfront, plus potential contingent payments totaling up to $30.25 per share, for a total deal value of about $285 million.
Why It Matters
The deal signals strong value potential for Day One Biopharmaceuticals, indicating confidence in its future prospects, which may positively influence its stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for potential fiduciary duty breaches related to its transaction with Day One Biopharmaceuticals.
Why It Matters
Investigations into fiduciary breaches can signal potential legal risks and financial instability, affecting Mersana's stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MRSN Stock
What is Mersana Therapeutics, Inc.'s (MRSN) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Mersana Therapeutics, Inc. (MRSN) has a median price target of $29.00. The highest price target is $50.00 and the lowest is $27.25.
Is MRSN stock a good investment in 2026?
According to current analyst ratings, MRSN has 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRSN stock?
Wall Street analysts predict MRSN stock could reach $29.00 in the next 12 months. This represents a 4.1% increase from the current price of $27.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mersana Therapeutics, Inc.'s business model?
Mersana Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on creating novel antibody-drug conjugates (ADCs) that target specific cancer cells. The company earns revenue through collaborations with major biopharmaceutical firms, funding for research and development, and potential future product sales from successful clinical trials.
What is the highest forecasted price for MRSN Mersana Therapeutics, Inc.?
The highest price target for MRSN is $50.00 from at , which represents a 79.5% increase from the current price of $27.85.
What is the lowest forecasted price for MRSN Mersana Therapeutics, Inc.?
The lowest price target for MRSN is $27.25 from at , which represents a -2.2% decrease from the current price of $27.85.
What is the overall MRSN consensus from analysts for Mersana Therapeutics, Inc.?
The overall analyst consensus for MRSN is neutral. Out of 13 Wall Street analysts, 0 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $29.00.
How accurate are MRSN stock price projections?
Stock price projections, including those for Mersana Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 6:14 PM UTC